I have taken a long position in INO here. INO is in human trials for covid-19 vaccine with safety results expected in late June. Multiple possible catalyst including further funding. NVAX just received $388 million from CEPI and with INO being one of the few in human trials for covid-19 vaccine already, further funding for INO is likely as well. This is not a...
Expect a significant appreciation in price leading up to the upcoming poster presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR virtual annual meeting.
$MRNA Bullish falling wedge Resistance: 65.16 Support: 47.56 Buy: $56.40 Stop loss: $50.99 Limit sell: $63.90 Notes: Still feel sketch about their "Secondary offering" it tells shareholders that they are going to take a giant ass pile of cash and set it on fire. However, as will all offerings... someone has to make money so you can decide if it is worth a...
Hello all! I will like to disclose that I have been an early investor in INO since 2008! So unlike a lot of others that are new to Inovio, I really know this company well. Do not listen to CITRON as they are speaking from ignorance and not knowing anything at all about what a company like INO does or is about. \ That been said... I have been keeping a close watch...
I've been actively trading the recent VBIV bull run, and I still expect the bull run to continue from now until year's end. However, the stock is up over 100% in a very short time, and this may be the correction to this rapid movement. I'm not actively trading this idea yet, but I will update the idea if I decide to short. Remember folks, just ideas!
nice broadening formation here.. can rip to 81 if it gets 72
IFFFFF the $1.98 - $2.00 support line holds and buying pressure increases, I expect to see a pretty big upward price movement for the day. Remember folks, just ideas!
I'm bull-ish on Novavax (see Related Idea). I think their approach to the COVID-19 vaccine is promising - their recombinant nanoparticle vaccine technology and Matrix-M adjuvant. They also have positive long-term prospects with their proprietary NanoFlu candidate. This is the big one to me. It's unclear whether COVID-19 becomes seasonal or not but influenza is...
Gilead Sciences , Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency...
VBIV is breaking out of a symmetrical triangle on 15min within a much larger ascending triangle on 4hr which may be a continuation pattern off of the local price bottom. I expect to see $1.50 within next 3 trading days.
Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020 Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS – human clinical study material expected to be available in Q4 2020 Expanded immunologic,...
Hey fellow Traders from TradingView, this is an update to the actual Situation and my previous Analysis If you agree with my Analysis or find it useful , please leave me a like for my work it would be greatly appreciated. Im still bullish and optimistic that BNTX participation will have a huge global impact. The stock seems to be news related, so expect it...
Possible pull back reasons: BTC halving: Millenials are into crypto and a lot of people made money June last year before the LTC halving. People are hyped because this is the last major halving for 4 years. And might be selling their stocks or fresh INO gains to get into BTC. PLUS miners usually plan ahead for the bitcoin halvings and buy extra equipment to not...
ONE OF THE 3 COMPANIES WITH HIGHEST CHANCE TO DEVELOPS COVID-19 VACCINE!
Bullish: Every week since the low has closed green except this week. Bearish: The last week of each month have been particularly bearish since January. The overwhelming bull trend that's taken place over the past few weeks have been disorienting. My bias is now leaning neutral. I will consider the downtrend on hold if the monthly closes above the 17th of April...
Trade Plan for Gilead Sciences. Will look to enter at bottom of uptrend channel (75.3) , Stop Loss once uptrend broken (74). Target Price at 86. Potential Price at 96. Personally will take profit at resistances as insurance. Upside for Gilead: 1a) Possible treatment for Covid-19 (Remdesivir) 1b) Possible 2nd wave of virus 2) Possible FDA approval of Arthritis...